A few studies reported that prolonged CSF-1R inhibition leads to an acquired resistance and tumor recurrence through activation of the PI3K pathway; the combination of PI3K blockade with CSF-1R inhibition prolonged survival in pre-clinical models [110]. This evidence concerns the gene CSF1R and neoplasm.